Viatris

Viatris makes and sells medicines that help people manage health conditions like heart disease and infections. It provides quality treatments to patients through pharmacies, hospitals, and government health programs. The company serves roughly 1 billion patients every year across more than 165 countries.

What is in the Medicine Cabinet?

• Iconic Brands: Well-known prescription drugs including Lipitor for cholesterol, Lyrica for nerve pain, and Viagra for erectile dysfunction.
• Generics: Lower-cost versions of brand-name drugs that meet the same safety and quality standards as the original products.
• Complex Medicines: Specialized treatments like Wixela Inhub for asthma and EpiPen auto-injectors for severe allergic reactions.
• Biosimilars: Highly similar versions of biological medicines used in areas such as oncology and immunology.
• Active Pharmaceutical Ingredients: Raw chemical components used to manufacture various antibacterial and cardiovascular drugs.

Recent Business Moves

• Acquired Aculys Pharma in October 2025 to gain rights to innovative neurological treatments in the Japan market.
• Divested the global over-the-counter business to Cooper Consumer Health in July 2024 to simplify operations.
• Sold the active pharmaceutical ingredient business in India to Matrix Pharma Private Limited in June 2024.
• Completed the sale of the women's healthcare business to Insud Pharma in March 2024.
• Contributed the biosimilars portfolio to Biocon Biologics in November 2022 in exchange for cash and an equity stake.

A Global Production Powerhouse

Viatris operates 27 manufacturing and distribution sites across five continents to ensure a steady supply of medicine. Its technical network includes thousands of scientists and regulatory experts who manage over 1,400 approved drug molecules.

Checking the Vital Signs

• Total revenue reached $14.3 billion in 2025, despite impacts from business divestitures and supply disruptions.
• Operating cash flow rose to $815.8 million in Q4 2025, a 69% increase from $482.7 million in Q4 2024.
• Free cash flow grew to $550.5 million in Q4 2025, up 67.2% from $329.3 million in the same period for 2024.
• The company returned over $1 billion to shareholders in 2025 through $500 million in share repurchases and $561 million in dividends.

The Bottom Line

Viatris has transitioned from a massive merger of two legacy businesses into a leaner organization focused on complex and innovative medicines. This evolution emphasizes higher-margin products and debt reduction to support long-term stability.